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December 2003. Patients were stratiﬁed into 2 cohorts: those
receiving OAB pharmacotherapy, including long-acting toltero-
dine or immediate- or extended-release oxybutynin and those
receiving non-pharmacologic management. Patients were
matched 1 :1 by the estimated propensity score for OAB phar-
macotherapy using a logistic regression model incorporating
selected demographic and clinical characteristics. Differences in
direct medical costs during follow-up were assessed using
descriptive statistics (Wilcoxon rank-sum tests) and multivariate
statistical techniques to adjust for differences in demographic
and clinical characteristics. RESULTS: A total of 1681 matched
pairs were identiﬁed. Patients’ mean ± SD age was 78 ± 8 years;
60% were women. After matching, all initial differences in
patient characteristics were not signiﬁcant. Mean ± SD OAB-
related costs ($244 ± $1763 for PT vs $857 ± $4438 for NPM;
p < 0.0001) and infection-related costs ($860 ± $6265 for PT vs
$1044 ± $6918 for NPM; p < 0.0001) were signiﬁcantly higher
in the NPM cohort compared with the PT cohort while depres-
sion-related ($245 ± $2755 for PT vs $229 ± $2319 for NPM;
p = NS) and fall/fracture-related costs ($380 ± $3115 for PT vs
$554 ± $4142 for NPM, p = NS) were similar. Pharmacy costs
were higher in the PT cohort, but total direct costs (OAB-related
and unrelated) were higher in the NPM group ($11,580 ±
$23,452 for PT vs $12,941 ± $21,938 for NPM; p = NS). After
adjusting for prognostic factors, total direct costs were signiﬁ-
cantly higher for NPM patients in multivariate analyses (p =
0.0091). CONCLUSIONS: Elderly patients receiving OAB phar-
macotherapy appear to have lower annual direct medical costs
compared with patients receiving non-pharmacologic manage-
ment. Careful consideration should be given to the selection 
of OAB treatment options from both clinical and economic 
perspectives.
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OBJECTIVES: The National Kidney Foundation’s Kidney
Disease Outcomes Quality Initiative Guidelines (K/DOQI) rec-
ommend monitoring intact parathyroid hormone levels (iPTH)
among patients with chronic kidney disease (CKD) whose GFR
falls between 15 and 59mL/min/1.73m2. Target ranges for iPTH
levels in CKD are based on expert opinion: patients in stage 3
should not exceed 70pg/mL; patients in stage 4 should not
exceed 110pg/mL. We investigated the shape of the relation
between iPTH levels and health care costs to offer evidence.
METHODS: We assembled a cohort of 830 HMO members
(1998–2004) with stage 3 or 4 CKD (using K/DOQI criteria) and
an iPTH test to measure health care costs in the year following
their index iPTH test. Costs were assigned by applying standard
unit costs to utilization. We compared the ratio of costs 
(geometric means) for quintiles of iPTH using natural log-
transformed, linear regression. RESULTS: Costs increased for
patients who exceeded one of the K/DOQI cut-offs for “ele-
vated” iPTH (110pg/mL), but costs in the highest quintiles of
iPTH were comparable to those in the lowest quintiles. Com-
pared with patients at or below the 20th percentile of iPTH (3
to 55pg/mL), we identiﬁed the following levels of relative excess
(or lower) cost: Percentile (GFR);95% CI;Range 21st to 40th
(56–99); +25%; -18% to +89% 41st to 60th (100–144); +50%;
-2% to +131% 61st to 80th (145–228); +1%; -47% to +30%.
Our estimates controlled for age, sex, most recent estimated GFR
(MDRD), annual cost before the index iPTH value, and mortal-
ity. CONCLUSIONS: iPTH levels predict cost, but not in the
expected dose-response relation; future studies should explore
why the rates of utilization were lower among patients with the
highest levels of iPTH.
URINARY/KIDNEY—Health Care Use & Policy Studies
PUK5
EPOETIN ALFA AND DARBEPOETIN ALFA DOSING PATTERNS
IN ANEMIC PRE-DIALYSIS CHRONIC KIDNEY DISEASE
PATIENTS
Mody S1, Padmanabhan V2, McKenzie RS1, Bookhart B1
1Ortho Biotech Clinical Affairs, LLC, Bridgewater, NJ, USA, 2Ortho
Biotech Products, L.P, Bridgewater, NJ, USA
OBJECTIVE: To evaluate current epoetin alfa (EPO) and dar-
bepoetin alfa (DARB) dosing patterns from 2004–2005 in
anemic pre-dialysis chronic kidney disease (CKD) patients receiv-
ing care in nephrology clinics. METHODS: A random panel of
approximately 250 nephrologists was requested bimonthly to
review the medical records of their last two anemic pre-dialysis
CKD patients seen who were currently receiving an erythro-
poiesis-stimulating therapy (EST). Data on patient demograph-
ics, co-morbid conditions, CKD status, EST dose, and frequency
of administration were collected every 2 months to evaluate
changes over time. RESULTS: A total of 943 patient charts were
reviewed from November 2004 through September 2005 (EPO:
528; DARB: 415). Patient demographics, comorbid conditions,
baseline hemoglobin, and renal function were similar between
groups. Weekly and extended (≥Q2W) dosing patterns were seen
in both groups (EPO: QW, 47%; Q2W, 32%; Q4W, 15%; Other,
5%; DARB: QW, 23%; Q2W, 41%; Q4W, 33%; Other, 3%).
The mean weekly doses over the course of the study (EPO:
10,302 units; DARB: 47mcg) corresponded to a dose only ratio
(units EPO: mcg DARB) of 219 :1, resulting in mean weekly
costs of $125 and $205 for EPO and DARB (based on 2005
wholesale acquisition costs), respectively. These weekly cost dif-
ferences were observed in patients both under and over the age
of 65. CONCLUSIONS: DARB was associated with a higher
mean weekly EST cost compared to EPO. These analyses can
guide healthcare providers and decision makers in recognizing
real-world dosing patterns and costs of ESTs for the treatment
of anemic pre-dialysis CKD patients.
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OBJECTIVE: A reauthorization program was implemented to
apply updated VA guidelines to identify patients that may be
maintained on less costly, equally efﬁcacious alternatives for
treatment of benign prostatic hypertrophy. Study objective is to
assess patient safety, effectiveness and costs incurred to direct
formulary policy post implementation. METHODS: This retro-
spective outcome and utilization analysis extracted patient, pre-
scription, and resource data speciﬁc to VASDHS. Eligible
patients required a current prescription for tamsulosin and a
reauthorization request submitted between March and July
2005. Denied requests underwent a retrospective chart review of
the 90-days following the submission while 90-day drug and
resource cost estimates were applied to those requests approved.
Outcomes of denials were reviewed for safety and effectiveness.
